NovaBay® Pharmaceuticals, Inc. (NYSE-AMEX: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, announced today the company has received acceptance to deliver a poster presentation at the 47th Annual Meeting of the Infectious Diseases Society of America October 29 – November 1, 2009 in Philadelphia.
The poster presentation will describe results from a new study of NVC-422, an Aganocide ®compound.
Presentation details are as follows:
Poster Title: In Vitro Evaluation of Stable Derivatives of the Chlorotaurines on Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis
Date/Time: Saturday, Oct 31, 2009, 12:30 PM – 2:00 PM
Abstract Number: 1056
Location: Poster Hall A
Author: Bahram E. Memarzadeh, PhD; NovaBay® Pharmaceuticals, Emeryville, CA.
“This important study investigates the potential of NVC-422 to penetrate an infected nail and eradicate fungal infection in a human nail model of Onychomycosis, said Dr. Memarzadeh, Senior Director of Pharmaceutical Development, NovaBay® Pharmaceuticals. “This is important data to demonstrate the future potential for NVC-422 in a very large market.”
About Aganocide® Compounds
The Aganocide® compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay® to mimic the body’s natural defense against infection. The Aganocide® compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. In preclinical trials, the Aganocide® compounds have shown to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.
About NovaBay® Pharmaceuticals, Inc.
NovaBay® Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay® has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions. NovaBay® has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay® and Aganocide® are trademarks of NovaBay® Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.
Cautionary Information Regarding Forward-Looking Statements
The statements in this press release of NovaBay’s expectations regarding NovaBay’s Aganocides penetrating infected nails and eradicating fungal infections in a human nail model thereby demonstrate the future potential for NVC-422 to treat Onychomycosis are forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in preclinical models may not be obtained in humans, and the risk that Aganocide® may not deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. Other risks relating to NovaBay® and its Aganocide® compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s Annual Report on Form 10-K, under the caption “Risk Factors” in Item 1A of Part I of that report, which was filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay® disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Aimee Corso, 310-780-2661